NBQX
Modify Date: 2024-01-05 17:15:25
NBQX structure
|
Common Name | NBQX | ||
|---|---|---|---|---|
| CAS Number | 118876-58-7 | Molecular Weight | 336.28000 | |
| Density | 2.005g/cm3 | Boiling Point | 613.386ºC at 760 mmHg | |
| Molecular Formula | C12H8N4O6S | Melting Point | 361ºC | |
| MSDS | Chinese USA | Flash Point | 324.764ºC | |
Use of NBQXNBQX is a highly selective and competitive AMPA receptor antagonist. |
| Name | 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione |
|---|---|
| Synonym | More Synonyms |
| Description | NBQX is a highly selective and competitive AMPA receptor antagonist. |
|---|---|
| Related Catalog | |
| Target |
AMPA receptor[1] |
| In Vitro | NBQX has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex[1]. |
| In Vivo | NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion[1]. NBQX provides potent anticonvulsant protection against AMPA. The ED50 values for the protection against AMPA-induced seizures by NBQX (30 min, i.p.) is 23.6 (11.6- 48.0)[2]. |
| Animal Admin | Rats[1] Male Sprague-Dawley rats weighing 350-390 g are used for study. 30 mg/kg of NBQX (2x15 mg/mL) is administered i.v. as a bolus dose followed by an infusion of 10 mg/kg/h for 4 h, the bolus dose and infusion are started immediately after MCA occlusion. Blood samples are taken from these animals at 1, 2, 3 and 4 h after the start of the infusion and the plasma level of NBQX in each sample is measured[1]. Mice[1] The time course for the anticonvulsant action of NBQX and of GYKI 52466 against AMPA-induced seizures is determined by pretreating groups (n=10) of Swiss mice with 30 and 60/zmol/kg NBQX or GYKI 52466 (i.p.) 15-120 min before challenging the mice with a convulsant dose of AMPA (5 nmol) i.c.v[2]. |
| References |
| Density | 2.005g/cm3 |
|---|---|
| Boiling Point | 613.386ºC at 760 mmHg |
| Melting Point | 361ºC |
| Molecular Formula | C12H8N4O6S |
| Molecular Weight | 336.28000 |
| Flash Point | 324.764ºC |
| Exact Mass | 336.01600 |
| PSA | 180.08000 |
| LogP | 2.22950 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.864 |
| Storage condition | -20℃ |
Synonym:2,3-Dihydroxy-6-nitro-7-sulphamoylbenzo(f)-quinoxaline 6-Nitro-7-sulphamoylbenzo(f)-quinoxaline-2,3-dion Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW
Not available. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. Inhalation: May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Chronic: Not available. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Ingestion: Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Section 7 - HANDLING and STORAGE Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Storage: Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.) Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 118876-58-7: Personal Protective Equipment Eyes: Not available. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: yellow Odor: Not available. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Specific Gravity/Density: Molecular Formula: C12H8N4O6S Molecular Weight: 336.1392 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials. Incompatibilities with Other Materials: Strong oxidizing agents. Hazardous Decomposition Products: Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 118876-58-7 unlisted. LD50/LC50: Not available. Carcinogenicity: NBQX - Not listed by ACGIH, IARC, or NTP. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: Not available. Risk Phrases: Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 118876-58-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 118876-58-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 118876-58-7 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A |
| Hazard Codes | Xi: Irritant; |
|---|---|
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26 |
| 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide hydrate FG 9202 |
| NBQX hydrate |
| 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide |
| NBQX disodium salt hydrate |
| NBQX |